Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — BioStock Global Forum 2024
15 slides from Expres2ion Biotech Holding Ab's conference presentation, May 30, 2024
Slide 1: BioStock Global Forum, 30 May 2024
weden 130 May 2024 healthier we BIg)
Slide 2: Disclaimer
expreSceion BIOTECH Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company"). Neither shall the presentat
Slide 3: About ExpreS2ion
expreSceion BIOTECH About ExpreS2ion ——— ExpreS2io. n Biotech Holding AB NU” ——~ Expre. Biotechno NS S2ion logies ApS \ AdaptVac ApS NY ExpreS2ion Biotech Holding AB | —_________ + Listed on the Nasdaq First North Growth Market since 2016 + Holding company for ExpreS2ion Biotechnologies ApS, which i
Slide 4: Pipeline and market size
expreSceion BIOTECH Discovery Lead opt CTA-enabling Phi Ph2 Ph3. Market size ES2B-CO001 >€10 HER2+ breast cancer Oncology Billion! (therapeutic) ee bs e 2 -ES2B 1002 Infectious >€2 Seeecyomecciovirus disease Billion? 5 8 (prevention) Exploratory >€2 Undisclosed Billion’ Pilates crave fey Meer i Brel
Slide 5: ExpreS2 platform proofs-of-concept
ExpreS2 platform proofs-of-concept + numerous additional pharmaceutical and biotech protein production projects “ * Influenza Cytomegalovirus Through partnership with ExpreS2ion has first right Copenhagen University to license Bi 4 Nipah and filovirus Influenza Through participation in Through parti
Slide 6: ES2B-C001 therapeutic breast cancer vaccine: Investment highlights
expreSceion BIOTECH ES2B-COO1 therapeutic breast cancer vaccine Investment highlights a Unmet medical need < N 7 Market size < NN _ Technical validation < Experienced team < * ExpreS2ion is developing a therapy for HER2+ breast cancer, the most common cancer ¢ Estimate total market size in 2026 of €
Slide 7: Breast Cancer — The most common cancer
expreSeion BIOTECH Breast Cancer — The most common cancer * 1in 8 womenwill be diagnosed with invasive breast cancer ¢ In approximately 25% of breast cancer tumours, HER2 is overexpressed, which is associated with a more aggressive disease, higher recurrence rate, and increased mortality! * 685,000
Slide 8: Competitive landscape - Drawbacks to current therapies leave room for improvement
expreSeion BIOTECH Competitive landscape - Drawbacks to current therapies leave room for improvement ra PERJETA! Monoclonal antibodies (mAbs) and “se pertuzumab | chemotherapy are the standard of care for most SN pel Antibody drug conjugates (ADC) are novel 8 stage Il and Ill HER2+ breast cancers af
Slide 9: ES2B-C001 description and benefits vs. commercial
expreSceion BIOTECH Description Benefits vs. commercial HER2-expressing cancers, Extracellular domain (ECD) of HER2 mAbs Indication in first instance HER2+ ___protein coupled to the Polyclonal antibodies generated by breast cancer (BC) Acinetobacter Phage 205 (AP205) ES2B-CO01 target numerous capsid
Slide 10: Overcomes Herceptin resistance
expreS2ion BIOTECH Overcomes Herceptin resistance The soft agar human cancer cell growth inhibition assay provides in vitro evidence ES2B-C001 trastuzuma Both Herceptin (trastuzumab) and ES2B-C001 inhibited growth in the trastuzumab-sensitive cells Trastuzumab- sensitive HER2+ human cancer cells! On
Slide 11: Tumor volume data
Vehicle Vehicle Vehicle 10 g ES2B-C001 ES2B-C001 ES2B-C001 g 1010 g i.m.i.m. i.m. 10 g ES2B-C001 ES2B-C001 ES2B-C001 g 10 10 g i.m.+Montanide i.m.+Montanide i.m.+Montanide 2.5 bleeding administration bleeding administration bleeding administration Tumor volume (cm3) 2.0 Mean ± SEM 2.5 2.52.5 1
Slide 12: Advancing our proprietary pipeline
expreSceion BIOTECH Advancing our proprietary pipeline ES2B-CO00!1: Therapeutic HER2+ breast cancer vaccine Preclinical Safety + Study completed in Q2 2024 ee §=6CMC (Chemistry, Manufacturing and Controls) + Drug substance manufacturing completed in May '24 + Drug product manufacturing initiated wit
Slide 13: Oncology Scientific Advisory Board
expreSceion BIOTECH Oncology Scientific Advisory Board Advised by the leading specialists in oncology and specifically breast cancer Dr. Giuseppe Curigliano, MD, PhD g == Dr. Ulrik Lassen, MD, PhD Professor at University of Copenhagen, Department of Clinical Medicine. In 2017, he was appointed Head
Slide 14: Rights issue
expreSceion BIOTECH Rights issue Subscription period June 12-27, subject to AGM vote Approximate allocation of proceeds * Amounting to approximately SEK 60 million * Subscription intentions and guarantee commitments of approximately 50%, or SEK 30 million * Includes two warrant series, for subscript
Slide 15: Investor Relations
Investor Relations
ExpreS2ion Biotech Holding — BioStock Global Forum 2024 on 6ix